The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general and as it pertains to head and neck squamous cell carcinoma. Side effects, resistance mechanisms, and therapeutic monitoring strategies pertaining to immunotherapy are discussed.
BaumanJECohenEFerrisRLAdelsteinDJBrizelDMRidgeJAO’SullivanBBurtnessBAButterfieldLHCarsonWE. et al. 2017. Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 123(7):1259–1271.
2.
BaumlJSeiwertTYPfisterDGWordenFLiuSVGilbertJSabaNFWeissJWirthLSukariA. et al. 2017. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 35(14):1542–1549.
3.
BlackburnSDShinHHainingWNZouTWorkmanCJPolleyABettsMRFreemanGJVignaliDAWherryEJ. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 10(1):29–37.
4.
BrinkmanJAFauschSCWeberJSKastWM. 2004. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther. 4(2):181–198.
5.
ChampiatSLambotteOBarreauEBelkhirRBerdelouACarbonnelFCauquilCChansonPCollinsMDurrbachA. et al. 2016. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 27(4):559–574.
6.
ChowLQHaddadRGuptaSMahipalAMehraRTaharaMBergerREderJPBurtnessBLeeSH. et al. 2016. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 34(32):3838–3845.
7.
CohenEHarringtonKJLe TourneauCDinisJLicitraLAhnMJSoriaAMachielsJPMachNMehraR. et al. 2017. Pembrolizumab versus standard of care for recurrent or metastatic head and neck squamous cell carcinoma: phase 3 KEYNOTE-040 trial. Ann Oncol. 28Suppl 5:mdx440.040.
8.
Concha-BenaventeFSrivastavaRMTrivediSLeiYChandranUSeethalaRRFreemanGJFerrisRL. 2016. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Cancer Res. 76(5):1031–1043.
9.
DavisMMKrogsgaardMHuppaJBSumenCPurbhooMAIrvineDJWuLCEhrlichL.2003. Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem. 72:717–742.
10.
de BiasiARVillena-VargasJAdusumilliPS. 2014. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 20(21):5384–5391.
11.
DunnGPBruceATIkedaHOldLJSchreiberRD. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3(11):991–998.
12.
FerrisRLBlumenscheinGJrFayetteJGuigayJColevasADLicitraLHarringtonKKasperSVokesEEEvenC. et al. 2016. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375(19):1856–1867.
13.
GrossoJFGoldbergMVGetnetDBrunoTCYenHRPyleKJHipkissEVignaliDAPardollDMDrakeCG. 2009. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 182(11):6659–6669.
14.
HodiFSButlerMObleDASeidenMVHaluskaFGKruseAMacraeSNelsonMCanningCLowyI. et al. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 105(8):3005–3010.
15.
HodiFSHwuWJKeffordRWeberJSDaudAHamidOPatnaikARibasARobertCGangadharTC. et al. 2016. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 34(13):1510–1517.
16.
JollerNKuchrooVK. 2017. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 410:127–156.
17.
JollerNLozanoEBurkettPRPatelBXiaoSZhuCXiaJTanTGSefikEYajnikV. et al. 2014. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 40(4):569–581.
18.
KussIHathawayBFerrisRLGoodingWWhitesideTL. 2004. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 10(11):3755–3762.
19.
KyiCHellmannMDWolchokJDChapmanPBPostowMA. 2014. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2:19.
20.
LarkinJHodiFSWolchokJD. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373(13):1270–1271.
21.
LevinSDTaftDWBrandtCSBucherCHowardEDChadwickEMJohnstonJHammondABontadelliKArdourelD. et al. 2011. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 41(4):902–915.
22.
López-AlbaiteroANayakJVOginoTMachandiaAGoodingWDeLeoABFerroneSFerrisRL. 2006. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 176(6):3402–3409.
23.
MalkhasyanKAZakhariaYMilhemM.2017. Quality-of-life outcomes in patients with advanced melanoma: a review of the literature. Pigment Cell Melanoma Res. 30(6):511–520.
24.
MulthoffGRadonsJ.2012. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2:58.
25.
O’DonnellJSLongGVScolyerRATengMWSmythMJ. 2017. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 52:71–81.
26.
O’DonnellJSSmythMJTengMW. 2016. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?Genome Med. 8(1):111.
27.
OkazakiTOkazakiIMWangJSugiuraDNakakiFYoshidaTKatoYFagarasanSMuramatsuMEtoT. et al. 2011. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 208(2):395–407.
28.
PardollDM.2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12(4):252–264.
29.
PedrosCCanonigo-BalancioAJKongKFAltmanA.2017. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity. JCI Insight. 2(23):95692.
30.
PeggsKSQuezadaSAChambersCAKormanAJAllisonJP. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 206(8):1717–1725.
31.
PittJMVetizouMDaillereRRobertiMPYamazakiTRoutyBLepagePBonecaIGChamaillardMKroemerG. et al. 2016. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 44(6):1255–1269.
32.
RiekeDTOchsenreitherSKlinghammerKSeiwertTYKlauschenFTinhoferIKeilholzU.2016. Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget. 7(46):75379–75393.
33.
SandinLCErikssonFEllmarkPLoskogASTottermanTHMangsboSM. 2014. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 3(1):e27614.
34.
SeiwertTYBurtnessBMehraRWeissJBergerREderJPHeathKMcClanahanTLuncefordJGauseC. et al. 2016. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17(7):956–965.
35.
SimpsonTRLiFMontalvo-OrtizWSepulvedaMABergerhoffKArceFRoddieCHenryJYYagitaHWolchokJD. et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 210(9):1695–1710.
36.
SzturzPVermorkenJB. 2017. Immunotherapy in head and neck cancer: aiming at extreme precision. BMC Med. 15(1):110.
37.
TaubeJMAndersRAYoungGDXuHSharmaRMcMillerTLChenSKleinAPPardollDMTopalianSL. et al. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4(127):127ra137.
38.
TaubeJMKleinABrahmerJRXuHPanXKimJHChenLPardollDMTopalianSLAndersRA. 2014. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 20(19):5064–5074.
39.
TermeMUllrichEAymericLMeinhardtKDesboisMDelahayeNViaudSRyffelBYagitaHKaplanskiG. et al. 2011. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71(16):5393–5399.
40.
TopalianSLHodiFSBrahmerJRGettingerSNSmithDCMcDermottDFPowderlyJDCarvajalRDSosmanJAAtkinsMB. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366(26):2443–2454.
41.
TopalianSLTaubeJMAndersRAPardollDM. 2016. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16(5):275–287.
WherryEJHaSJKaechSMHainingWNSarkarSKaliaVSubramaniamSBlattmanJNBarberDLAhmedR.2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 27(4):670–684.
44.
WherryEJKurachiM.2015. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15(8):486–499.
45.
WolchokJDChiarion-SileniVGonzalezRRutkowskiPGrobJJCoweyCLLaoCDWagstaffJSchadendorfDFerrucciPF. et al. 2017. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 377(14):1345–1356.
46.
WolchokJDHoosAO’DaySWeberJSHamidOLebbeCMaioMBinderMBohnsackONicholG. et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15(23):7412–7420.
47.
WorkmanCJVignaliDA. 2005. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 174(2):688–695.
